The preliminary programme is based on the topics specified by the ICOC, ISOCAM and Local Scientific committees and the response of colleagues who have contacted the organisers. The final programme will be released following the deadline of submission of abstracts and the selection of oral and poster presentations. All the presentations need the submission of an abstract by the deadline (10th August, 2011).
Chelation studies and chelation therapy of diseases related to iron, other essential metals, actinide, heavy and other non essential metals. Organometallics. Chelators and chelating drugs: Design, chemistry, biochemistry, toxicity and pharmacology. Deferiprone, Deferasirox, Deferoxamine. Experimental chelating drugs. Recent Advances in thalassaemia and iron chelation therapy All aspects and treatment of haemoglobinopathies, cancer, infectious, inflammatory, neurodegenerative, cardiac, liver and kidney diseases. Diabetes. Ageing. Antioxidants and antioxidant therapies. Oxidative stress and tissue damage Free radical imbalance, toxicity and diseases Metal metabolism, imbalance and toxicity. Proteins of metal metabolism and toxicity Diagnostics of metals and of free radicals Metallogenomics. Pharmacogenomics. Nutrigenomics Blood rheology, components and substitutes Ethical, educational and environmental issues. Patients and doctors question time
Professor Aaseth Jan, Andersen Ole (Innlandet Hospital Trust, Norway; Roskilde University, Denmark) Experimental copper chelation - clinical implications. Professor Aessopos Athanasios (University of Athens Medical School, Athens, Greece) Clinical forms of cardiac involvement in hemoglobinopathies Professor Afanasiev Igor (Institute of Vitamin Research, Moscow, Russia) Reactive oxygen species signalling in cancer. Free radicals and epigenetics. Professor Anderson Greg (Queensland Institute of Medical Research Brisbane Hospital, Brisbane Australia) Regulating iron homeostasis: links to primary and secondary iron loading Andayi Andrew W (Department of Chemistry University of Cape Town, Cape Town ,South Africa) Overcoming drug resistant malaria; Mode of antiplasmodial activity of hydroxypyridinone - aminoquinoline hybrids with respect to chelation and haemozoin inhibition. Professor Aydinok Yesim (Ege University Medical School, Department of Pediatric Hematology, Izmir, Turkey) Iron chelation therapy: Removal of cardiac iron Professor Cabantchik Z Ioav (Biochemistrty, Hebrew University of Jerusalem, Jerusalem, Israel) Relocating iron. A novel therapeutic modality of chelation Professor Ceci Adriana (on behalf of the DEEP Consorzium) (Biological and Pharmacological Evaluation Consorzium (CVBF), Italy) Iron overload in very young children: epidemiology, clinical presentation, diagnostic tools and appropriate treatment. Professor Chevion Mottie (The Hebrew University of Jerusalem, Hadassah Medical School, Jerusalem, Israel) Iron homeostasis in the ischemic heart: how could iron protect the the normal and diabetic myocardium? Dr Evripidou Andri et al (Dept Gynaecology, Paphos General Hospital, Paphos, Cyprus) Monitoring of serum ferritin and haemoglobin levels in pregnant women treated with iron supplements Dr Farmakis Dimitrios (University of Athens Medical School, Athens, Greece) Pathophysiology of the cardiac involvement in hemoglobinopathies Professor Fibach Eitan and Prus Eugenia (Hadassah – Hebrew University Medical Center, Jerusalem, Israel) Labile iron and oxidative stress in erythroid cells and the effects of chelators Professor Flora SJS (Division of Pharmacology & Toxicology Defence R&D, Gwalior, India) Recent developments in the search for a new chelator for treating chronic arsenic poisoning Dr Grosse Regine (University Medical Centre Hamburg-Eppendorf, Germany) a) Correlation between exocrine pancreatic function and heart iron b) Iron in neurodegenerative disorders Dr Hadipour Dehshal M.and Manshadi M. (Iranian Blood Transfusion Organization, Tehran, Iran) Increase of total antioxidant activity following vitamin C and vitamin E administration to β-thalassaemic patients. Professor Hershko Chaim (Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel) Non-transferrin-bound-iron (NTBI). (Session) Dr Kolnagou A et al (Postgraduate Research Institute, Science, Techn., Environ & Med. Limassol, Cyprus) a) How to achieve and maintain normal range body iron store levels (NRBISL) in thalasssaemia patients b) Long term follow up of deferiprone (L1) treated thalassaemia patients with normal range body iron store levels (NRBISL) Professor Konishi Tetsuya (Dept Functional and Analytical Food Sciences, Niigata University, Niigata, Japan) Multifunctional property of antioxidant food factors Professor Kontoghiorghes GJ et al (Postgraduate Research Institute, Science, Techn., Environ & Med. Limassol, Cyprus) a) Golden era in iron chelation therapy: complete treatment of iron overload and effects on the morbidity and mortality of iron loaded patients b) Deferiprone as a universal antioxidant in neurodegenerative, infectious, inflammatory, neoplasmic and other diseases c) Toxicity of chelating drugs and other chelators Dr Kontos Christos, Michaelides E, Charalambous E, Theocharous E, Stylianou A Moutiris J, Mavrommatis P. (Dept Cardiology, Paphos General Hospital, Paphos, Cyprus) Case report: Myocarditis mimicking acute myocardial infarction in a teenager Professor Li Changgang, Mai Huirong , Wang Ying, Liu Riyang, Zhang Xinhua, WW Chu, WY Au (Shenzhen Children’s Hospital , Guangdong Province, Shenzhen, China) Research of heart and liver iron deposition status in patients with β thalassaemia intermedia and major in China mainland Professor Lipinski Boguslaw (Joslin Diabetes Center, Harvard Medical School, USA) Pathophysiological significance of the interaction of iron with fibrinogen Professor Liu Gang (Department of Radiology, University of Utah, Salt Lake City, Utah, USA) New chelating agents as inhibitors of amyloid polypeptide fibril formation and nephrotoxicity Professor Marx JJM (University Medical Centre, Utrecht, The Netherlands) New insights in iron metabolism. (Session) Dr Patrinos George P (Department of Pharmacology, University of Patras, Patras, Greece) Kruppel-like factor 1 (KLF1) as a novel therapeutic target for β-type hemoglobinopathies Professor Pattichis Costas S, Antoniades A et al (University of Cyprus, Nicosia, Cyprus) Medical education sharing across european institutions. (Session) Dr Poyiadji Stella, Papaharilaou Yannis, Georgiou Georgios and Andreja Zupancic (University of Cyprus, Cyprus & University of Ljubljana, Slovenia) The effect of volume expanders on blood rheology and hemodynamics simulations Dr Phylactides Marios and Kleanthous Marina (Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus) A study of histone deacetylase inhibitors as potential haemoglobin F inducers Dr Polyakov NE, Focsan AL, Bowman MK and Kispert LD (Institute of Chemical Kinetics & Combustion, Novosibirsk, Russia) Chelate complexes of carotenoid astaxanthin with metal ions Dr Restivo Pantalone G and Calvaruso G (UOC Ematologia II, Azienda Ospedaliera Ospedali Riuniti V. Sofia - Palermo, Italy) Thalassemia and hepatocellular carcinoma: clinical findings, outcome and long term follow-up in a single centre experience. Dr Sharp Paul (Nutritional Sciences Division, King's College London, London, UK) Nutrigenomic regulation of dietary iron absorption Dr Ricchi Paolo (1) and Pepe Alessia (2) (AORN Cardarelli, Centro delle Microcitemie, Naples, Italy (1) Fondazione “G. Monasterio” CNR-Regione Toscana & Institute of Clinical Physiology, Pisa, Italy (2)) The use of combined deferiprone and deferoxamine regimen in clinical practice for the treatment of myocardial iron overload in thalassemia Professor Richardson DR, Lovejoy DB., Jansson, PJ, Brunk UT, Wong J, Ponka P (Dept of Pathology and Bosch Institute, University of Sydney, Sydney, Australia) The celator Dp44mT mediates anti-tumor activity by forming a redox-active copper complex that accumulates in lysosomes Professor Richardson D R, Yu Y, Rahmanto YS (Dept of Pathology and Bosch Institute, University of Sydney, Sydney, Australia) Bp44mT: An orally-active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. Dr Rigano P, Restivo Pantalone G and Calvaruso G (UOC Ematologia II, Azienda Ospedaliera Ospedali Riuniti V.Sofia - Palermo, Italy) Sequential alternating deferasirox-deferiprone versus deferasirox or deferiprone multicentre randomized trial: an on-going experience Dr Chris Tselepis (School of Cancer Sciences, University of Birmingham, Birmingham, U.K) Irons in the cancer fire Dr Tsironi Maria (University of Sparta, Sparta, Greece) Management of cardiac involvement in hemoglobinopathies Dr Vraka Panayiota S, Papantoniou Constantinos, Michaelides Ioannis, Zouvani Ioanna (Dept Histopathology, Nicosia General Hospital, Cyprus) K-RAS mutations and colorectal cancer in Cypriot Patients Dr Yazman Dilek (Haematology Department, Turkish Cypriot General Hospital, Nicosia, Cyprus) How does liver and cardiac hemosiderosis affect respiratory lung function Professor Zupancic Valant Andreja (University of Ljubljana, Ljubljana, Slovenia) The fluidity of blood at different levels of oxygen content |